The suppression of MYC’s activities by BET inhibitors (BETi) was reported in various types of tumors [55,56], and Fiorentino et al. [57] demonstrated that the therapeutic effects of BET inhibition include a decrease in MYC expression and suppression of its downstream targets, ultimately leading to inhibition of tumor cell proliferation. Here, MYC is linked to neoplasm.